While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]
If nausea persists or becomes intolerable, consult your healthcare provider about possible adjustments to your dosage
Glucagon receptor activation was previously considered counterproductive for weight loss because glucagon raises blood sugar
Most patients begin with a 0.25 mg dose in week one, then progress through 0.5 mg, 1.0 mg, 1.7 mg, and up to 2.4 mg maintenance depending on tolerability and clinical response
This allows for an obsessive level of quality control at every stage, ensuring the final lyophilized product that arrives at your lab is of the highest possible purity and integrity
If prescribed, your subscription includes: Personalized Treatment Plans Medication and Supplies Shipping to Your Door Purchase Options How Henry Works Get started with no insurance required
